Wednesday, 4 January 2017

Growth Prospects of the EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025 is a new market research publication announced by Reportstack. Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease (CVD), and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial.
The clinical diagnostic criteria for dyslipidemia and serum lipid abnormalities vary across countries and depend on the disease treatment and management guidelines that are followed in each country. Guidelines for the detection, evaluation, treatment, and management of dyslipidemia, as well as the prevention of associated CVD, are updated periodically, which has led to further differences over the past several decades in how the prevalence of dyslipidemia is assessed in different studies. For this analysis, The epidemiologists estimated the total prevalent cases of serum lipid abnormalities according to country-specific cut-offs.
In 2015, there were 580,825,262 total prevalent cases of dyslipidemia in the 8MM. This is forecast to grow to 680,288,645 by 2025, at an Annual Growth Rate (AGR) of 1.71%. Urban China made up the majority of the total prevalent cases in the 8MM throughout the forecast period, and will also experience the highest growth from 274,741,284 total prevalent cases of dyslipidemia in 2015 to 348,184,445 cases by 2025, at an AGR of 2.67%. The US is forecast to grow at an AGR of 1.34%, from 133,104,335 total prevalent cases of dyslipidemia in 2015 to 150,918,348 cases by 2025. In the 8MM, there were 317,925,626 diagnosed prevalent cases of dyslipidemia, which is forecast to grow to 370,440,489 by 2025.
The epidemiologists used comprehensive, country-specific data from population-based national health surveys, such as the NHANES in the US and the CHNS in urban China. Additionally, data from peer-reviewed journal articles were utilized to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, as well as other therapeutically significant patient populations including the diagnosed prevalent cases of dyslipidemia and the total prevalent cases of FH.
Scope
- The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of dyslipidemia-which are defined as elevated low-density lipoprotein cholesterol (LDL-C), high triglycerides (TG), or low levels of high-density lipoprotein cholesterol (HDL-C)-as well as the total prevalent cases of increased LDL-C, and very high TG, segmented by sex and age. Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) and very high TG in these markets.
- The dyslipidemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
The Dyslipidemia EpiCast report will allow you to - 
- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
- Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.
- Understand the distribution of types of dyslipidemia and FH in these markets.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

Market Research on EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025

EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025 is a new market research publication announced by Reportstack. Ovarian cancer (OC; International Classification of Diseases, Revision 10 [ICD-10] code: C56) and cancer of the fallopian tubes and other uterine adnexa (ICD-10: C57) are leading causes of cancer mortality in women. Cancer of the ovary, fallopian tubes, and other uterine adnexa are collectively referred to as OC throughout this report. In the US, the American Cancer Society reports that OC accounts for more deaths than any other cancer of the female reproductive system.
The epidemiologists forecast the diagnosed incident cases of OC in the 7MM, to increase from 68,804 cases in 2015 to 77,457 cases in 2025, at an Annual Growth Rate (AGR) of 1.26%. The US will have the highest number of diagnosed incident cases of OC in the 7MM throughout the forecast period. The five year diagnosed prevalent cases of OC are also expected to increase from 191,345 cases in 2015 to 218,905 cases in 2025, at an AGR of 1.44%. Additionally, in 2015, there were 191,345 five-year diagnosed prevalent cases of OC in the 7MM, which is expected to increase to 218,905 cases by 2025, at an AGR of 1.44%. Among the 7MM, the US had the highest number of five-year diagnosed prevalent cases of OC in 2015 and 2025, at 73,597 cases and 89,778 cases, respectively.
The epidemiological forecast for the diagnosed incident and five-year diagnosed prevalent cases of OC in the 7MM is supported by age- and sex-specific incidence data drawn from national cancer registries. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific population-based studies that are representative of the national population in the respective markets. The use of a consistent methodology across the 7MM to forecast the diagnosed incident cases and the five-year diagnosed prevalent cases of OC allows for a meaningful comparison of the forecast diagnosed incident cases and the forecast five-year diagnosed prevalent cases of OC in these markets.
Scope
- The Ovarian Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for OC in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of OC segmented by sex, age (beginning at 18 years and ending at =85 years). Additionally, it includes a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of OC and in these markets.
- The OC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The OC EpiCast report will allow you to - 
- Develop business strategies by understanding the trends shaping and driving the global OC market.
- Quantify patient populations in the global OC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for OC therapeutics in each of the markets covered. 
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

Recent Research into the Hydropower in Colombia Market to 2030, Update 2016

Hydropower in Colombia, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles is a new market research publication announced by Reportstack. This report provides in depth analysis on global renewable power market and global hydropower market with forecasts up to 2030. The report analyzes the power market scenario in Colombia (includes conventional thermal, nuclear, large hydro and renewable energy sources) and provides future outlook with forecasts up to 2030. The research details renewable power market outlook in the country (includes hydro, small hydro, biopower and solar PV) and provides forecasts up to 2030. The report highlights installed capacity and power generation trends from 2006 to 2030 in Colombia hydropower market. A detailed coverage of renewable energy policy framework governing the market with specific policies pertaining to hydropower is provided in the report. The research also provides company snapshots of some of the major market participants.
Scope
The report analyses global renewable power market, global hydropower market, Colombia power market, Colombia renewable power market and Colombia hydropower market. The scope of the research includes - 
- A brief introduction on global carbon emissions and global primary energy consumption.
- An overview on global renewable power market, highlighting installed capacity trends, generation trends and installed capacity split by various renewable power sources. The information is covered for the historical period 2006-2015 (unless specified) and forecast period 2015-2030.
- Renewable power sources include wind (both onshore and offshore), solar photovoltaic (PV), concentrated solar power (CSP), small hydropower (SHP), biomass, biogas and geothermal.
- Detailed overview of the global hydropower market with installed capacity and generation trends, installed capacity split by major hydropower countries in 2015 and key owners information of various regions.
- Power market scenario in Colombia and provides detailed market overview, installed capacity and power generation trends by various fuel types (includes thermal conventional, nuclear, large hydro and renewable energy sources) with forecasts up to 2030.
- An overview on Colombia renewable power market, highlighting installed capacity trends (2006-2030), generation trends(2006-2030) and installed capacity split by various renewable power sources in 2015.
- Detailed overview of Colombia hydropower market with installed capacity and generation trends and major active and upcoming hydro projects.
- Deal analysis of Colombia hydropower market. Deals are analyzed on the basis of mergers, acquisitions, partnership, asset finance, debt offering, equity offering, private equity (PE) and venture capitalists (VC).
- Key policies and regulatory framework supporting the development of renewable power sources in general and hydropower in particular.
- Company snapshots of some of the major market participants in the country.
Reasons to buy
- The report will enhance your decision making capability in a more rapid and time sensitive manner.
- Identify key growth and investment opportunities in Colombia hydropower market.
- Facilitate decision-making based on strong historic and forecast data for hydropower market.
- Position yourself to gain the maximum advantage of the industry’s growth potential.
- Develop strategies based on the latest regulatory events.
- Identify key partners and business development avenues.
- Understand and respond to your competitors’ business structure, strategy and prospects.
Companies Mentioned
Isagen S.A. E.S.P. Endesa, S.A. Empresas Publicas De Medellin E.S.P. Empresa De Energia Del Pacifico S.A. E.S.P. Emgesa S.A. ESP
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

Tuesday, 3 January 2017

New Research Explores on United States Influenza Vaccine Market 2016 to 2022

United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022 is a new market research publication announced by Reportstack. United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Companies Mentioned
Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca, Protein Sciences Corporation, Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, VaxInnate
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

Market Review on Zika Virus Vaccines by Company Profile, Deals Type, Funding, Clinical Trials Insight, Regulatory Landscape & Recent Development

Zika Virus Vaccines by Company Profile, Deals Type, Funding, Clinical Trials Insight, Regulatory Landscape & Recent Development is a new market research publication announced by Reportstack. It is predicted that Zika virus vaccines shot will available to the public by 2018.
Zika virus is an emerging viral disease that is transmitted through the bite of an infected mosquito, primarily Aedes aegypti, the same vector that transmits chikungunya, dengue and yellow fever. Zika has a similar epidemiology, clinical presentation and transmission cycle in urban environments as chikungunya and dengue, although it generally causes milder illness.
The highest risk is to pregnant women due to the connection the virus has with serious birth defects. Pregnant women who contract the virus have a high possibility of giving birth to a baby with microcephaly, a neurodevelopment disorder, where a baby is born with an unusually small head due to abnormal brain development in the womb or after birth. Complications of this disorder include seizures and developmental issues.
Due to the serious nature of global risk, the WHO has declared the microcephaly cases associated with the Zika virus a Public Health Emergency of International Concern (PHEIC). With no vaccines or cure the virus and its risks are expected to continue to spread. The WHO is predicting up to 4 Million Zika cases in the Americas by 2016 and the World Bank is projecting the short-term economic impact for 2016, in Latin America and the Caribbean to be about US$3.5 Billion.
With fears of Zika virus reaching new heights, Zika virus vaccines are gaining popularity. Many Government agencies and research institutes support pharmaceutical companies for the development & manufacturing of Zika virus vaccines. It is predicted that Zika virus vaccines shot will available to the public by 2018.
The research report presents a comprehensive study of the Zika virus vaccines with details. It provides essential insights of introduction of Zika virus, current situation and areas with Zika virus and funding in Zika virus vaccines research. Additionally, the report includes assessment of clinical trials and regulatory landscape of Zika virus vaccines development. Key trends in terms of partnerships, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the Zika virus vaccines development such as Sanofi Pasteur, ImmunoVaccines Inc, Inovio Pharmaceuticals, Inc, Valneva, Bharat Biotech International Pvt. Ltd., NewLink Genetics. The major players are evaluated on various parameters such as company overview, product outlook and Zika virus vaccines latest development and trends.
Companies Mentioned
Sanofi Pasteur, ImmunoVaccines Inc, Inovio Pharmaceuticals, Inc, Valneva, Bharat Biotech International Pvt. Ltd., NewLink Genetics
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

New Report Covers Acrylic Acid Industry in Spain to 2020

Acrylic Acid Industry Outlook in Spain to 2020 - Market Size, Price Trends and Trade Balance is a new market research publication announced by Reportstack. This report provides in-depth coverage of Spain’s Acrylic Acid industry and presents major market trends. The report covers historical and forecast market size, demand and production forecasts, end-use demand details, price trends and trade balance data.
Scope
- Acrylic Acid industry market dynamics in Spain from 2006 to 2020, consisting of market size, demand and production outlook, demand by end-use sector, and average prices
- Trade balance data from 2006 to 2020, including import and export data and net exports and imports as a percentage of demand
Reasons to buy
- Obtain up-to-date information on Spain’s Acrylic Acid industry
- Benefit from the advanced insights and analysis
- Identify the macro and microeconomic trends affecting the industry
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

In-Depth Research on Acrylic Acid Industry in Brazil to 2020

Acrylic Acid Industry Outlook in Brazil to 2020 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants is a new market research publication announced by Reportstack. This report provides in-depth coverage of Brazil’s Acrylic Acid industry and presents major market trends. The report covers Brazil’s Acrylic Acid plants and presents installed capacity by production process and technology. It also gives historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the country’s leading Acrylic Acid producers to provide comprehensive coverage of all parameters of the Acrylic Acid industry.
Scope
- Acrylic Acid industry supply scenario in Brazil from 2006 to 2020, comprising plant capacity growth and installed plant capacity by production process and technology
- Detailed information of all active plants and planned Acrylic Acid projects in Brazil with capacity forecasts to 2020 and additional details such as production process, technology, operator and equity
- Acrylic Acid industry market dynamics in Brazil from 2006 to 2020, consisting of market size, demand and production outlook, demand by end-use sector, and average prices
- Trade balance data from 2006 to 2020, including import and export data and net exports and imports as a percentage of demand
- Company snapshots, including company overview, business description and information on current and upcoming Acrylic Acid plants
- Company capacity shares for key Acrylic Acid producers
Reasons to buy
- Obtain up-to-date information on Brazil’s Acrylic Acid industry
- Benefit from the advanced insights and analysis
- Identify the macro and microeconomic trends affecting the industry
- Understand the market positioning of the country’s Acrylic Acid producers
- Learn about opportunities in the Acrylic Acid industry
- Develop market-entry and market-expansion strategies
- Benchmark your operations and strategies against those of major companies
Companies Mentioned
BASF SE
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###